

Striatal dopamine integrates cost, benefit and motivation

Neir Eshel^{*1}, Gavin C. Toupponse¹, Allan R. Wang¹, Amber K. Osterman¹, Amei N. Shank¹, Alexandra M. Groome^{1,2}, Lara Taniguchi^{1,3}, Daniel F. Cardozo Pinto¹, Jason Tucciarone¹, Brandon S. Bentzley^{1,4}, Robert C. Malenka^{*1}

*co-corresponding authors

¹Nancy Pritzker Laboratory, Dept. of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305

²Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York, NY 10029

³Graduate Program in Neurobiology and Behavior, University of California Irvine, Irvine, CA 92697

⁴Magnus Medical, Burlingame, CA 94010

1 **ABSTRACT**

2 **Dopamine (DA) release in the ventral and dorsal striatum has been linked to reward**
3 **processing and motivation, but there are longstanding controversies about whether DA**
4 **release in these key target structures primarily reflects costs or benefits, and how these**
5 **signals vary with motivation. Here we apply behavioral economic principles to generate**
6 **demand curves for rewards while directly measuring DA release in the nucleus**
7 **accumbens (NAc) and dorsolateral striatum (DLS) via a genetically-encoded sensor. By**
8 **independently varying costs and benefits, we reveal that DA release in both structures**
9 **incorporates reward magnitude and sunk cost. Surprisingly, motivation was inversely**
10 **correlated with reward-evoked DA release; the higher the motivation for rewards the**
11 **lower the reward-evoked DA release. These relationships between DA release, cost and**
12 **motivation remained identical when we used optogenetic activation of striatal DA inputs**
13 **as a reward. Our results reconcile previous disparate findings by demonstrating that**
14 **during operant tasks, striatal DA release simultaneously encodes cost, benefit and**
15 **motivation but in distinct manners over different time scales.**

16

17 **INTRODUCTION**

18 Decision making requires a consideration of both costs and benefits, as influenced by
19 motivation. Although mesolimbic DA release is crucial for reward learning and therefore decision
20 making¹⁻⁴, prior studies have disagreed over its role in encoding costs, benefits or motivation.
21 On the one hand, disruptions to DA signaling in the NAc with pharmacological manipulations or
22 lesions bias animals towards low-cost, less-preferred rewards rather than high-cost, more-
23 preferred rewards without affecting reward preference or overall consumption⁵⁻⁸. These results
24 led to the conclusion that NAc DA release primarily mediates cost calculations; that is, how
25 much effort an animal exerts to obtain rewards. However, these studies often confounded cost
26 and benefit by varying both simultaneously, and used tools that could not examine how DA

27 activity dynamics in specific target structures underlie these behaviors. In contrast, studies of
28 DA activity dynamics during instrumental tasks suggest that striatal DA more reliably encodes
29 prospective benefit, not cost^{9–14}. These studies, however, were mostly correlational and did not
30 exploit causal tools such as optogenetics to explore how DA neuron activity directly influences
31 behavior. Furthermore, DA recording studies have rarely explored changes in motivational state
32 between individuals or across time except in studies of addiction, where there is longstanding
33 debate over whether striatal DA release is sensitized¹⁵ or depleted¹⁶ once individuals transition
34 to a highly-motivated, addicted state.

35 To address these limitations of previous work, we established a simple operant task that
36 independently varies costs and benefits to generate behavioral economic demand curves in
37 response to sucrose rewards or optogenetic stimulation of DA inputs. This approach yields a
38 quantitative metric of motivation, defined by the willingness to overcome cost, independently
39 from reward dose or preferred consumption at no cost. At the same time, we measured striatal
40 DA release using a genetically-encoded sensor, allowing us to test how striatal DA release
41 reflects costs, benefits and motivational state. We find that striatal DA release integrates cost
42 and benefit on a trial-by-trial basis, and surprisingly, that high motivation dampens these
43 signals. These findings reconcile discrepancies between prior studies on DA and help clarify the
44 role of striatal DA signals in motivated behavior.

45

46 **DA release in NAc and DLS signals both cost and benefit**

47 Mice learned to poke in an active nosepoke hole for access to sucrose reward, accompanied by
48 a brief light-sound cue (Fig. 1a). Over training, mice increased the number of rewards earned in
49 each session and decreased their latency to consume each reward (Fig. 1b). Once they
50 reached a behavioral criterion (see Methods), mice advanced to economic demand sessions, in
51 which we varied the fixed ratio (FR, number of pokes required per reward) in 10-minute bins
52 over 50 minutes (Fig. 1a). We considered the FR as the “cost” of reward. For each session,

53 reward “benefit” was fixed at a single combination of sucrose concentration and quantity.
54 Between sessions, however, we varied the concentration and quantity, such that mice
55 experienced four different benefits. As expected, mouse operant behavior was sensitive to both
56 reward benefit (Fig. 1c, left) and cost (Fig. 1c, right).

57 While mice performed this task, we used fiber photometry and the fluorescent sensor
58 GRAB-DA¹⁷ to record DA release in two striatal regions (Extended Data Fig. 1): the NAc core,
59 vital to reward learning and addiction¹⁸; and the DLS, long linked to movement initiation and
60 habit formation¹⁹. In one influential theory, demand for drugs of abuse begins with DA release in
61 the NAc, which then spirals up to the DLS once behavior becomes habitual²⁰. However,
62 compared to the NAc, many fewer studies have recorded DA release in the DLS during reward
63 tasks.

64 We aligned our recordings to the cue denoting reward availability, as this cue stayed
65 identical in all conditions even as the cost and benefit varied. Thus, any observed changes in
66 DA release could not be due to the sensory qualities of the stimulus, but rather to the perceived
67 meaning of the associated reward. As expected, we found that increased sucrose concentration
68 (Fig. 1d) and quantity (Fig. 1f) enhanced cued DA release in the NAc. DLS DA exhibited the
69 same pattern (Fig. 1e and 1g), although the kinetics of the DA response in DLS was strikingly
70 faster than that observed in the NAc.

71 Surprisingly, increased cost clearly enhanced DA responses in both regions (Fig. 1h, i),
72 despite the cue and reward being held constant. This effect was not due to differences in the
73 amount of time between rewards, because even when we kept this time interval constant, DA
74 release increased with increasing FR (Extended Data Fig. 2a, b). To determine whether the
75 effect of cost on DA release might relate to the order the FRs were presented, we conducted
76 two additional experiments. In one, we ran mice through the five FRs on different days, and still
77 found the same effect (Extended Data Fig. 2c, d). In a second control experiment, we ran new
78 cohorts of mice through two separate sessions: one where FR1 preceded FR10, and another

79 where FR10 preceded FR1. Regardless of order, DA release was larger for the higher FR
80 (Extended Data Fig. 2e-h). We conclude that in both striatal regions, DA encodes both benefit
81 and cost and that (sunk) cost positively correlates with DA release.

82

83 **Economic demand curves dissociate consumption from motivation**

84 To make rational decisions, individuals must combine cost and benefit to determine if the benefit
85 is worth the cost. This cost-benefit calculus is at the heart of motivation²¹. To measure
86 motivation, we turned to the classic economic analysis of demand curves^{22,23}. For each session,
87 we plotted reward consumption as a function of cost (Fig. 2a), revealing two orthogonal
88 parameters: Q_0 , the preferred level of consumption at no cost; and alpha, the sensitivity of
89 consumption to cost (i.e., elasticity). Q_0 is the y-intercept of the demand curve and is influenced
90 predominantly by overall reward consumption or reward rate. In contrast, alpha, which depends
91 on the demand curve's slope, is inversely proportional to the subject's motivation to obtain a
92 reward²⁴.

93 To validate that our analyses accurately reflected the consistency in subjects' behavior,
94 we repeated the same demand curve assays with a constant sucrose reward on consecutive
95 days and found that our metrics for motivation (Fig. 2b) and free consumption (Fig. 2c)
96 remained consistent, with minor day-to-day variability. Furthermore, varying the reward
97 magnitude did not cause changes in alpha, our measure of motivation (Fig. 2d), but did cause
98 changes in Q_0 , the free consumption parameter (Fig. 2e). This dissociation between motivation
99 and free consumption is expected²², and helps ensure that the alpha parameter does not simply
100 reflect the dose of the reward, but rather the reward's motivational value. In a typical subject,
101 free consumption varied from session to session as different sucrose rewards were provided
102 (Fig. 2f, left graph), but normalizing each demand curve by the free consumption (Fig. 2f, right
103 graph) revealed that alpha, the slope of the curve and hence the motivational pull of sucrose,
104 remained consistent despite changes in dose.

105 As a final test of the validity of the task, we asked whether the alpha parameter predicted
106 another common metric for motivation: tolerance to punishment. In this new task, mice received
107 sucrose reward at FR5 on 70% of trials, and in the remaining 30% of trials, they received both
108 sucrose reward and a mild footshock (Fig. 2g). We found that the motivation parameter
109 ($1/\alpha$) calculated from previous demand curve assays (Fig. 2h), but not the free consumption
110 parameter, Q_0 (Fig. 2i), predicted the number of shocks a subject was willing to experience to
111 obtain the reward. These results provide strong evidence that the behavioral economics task
112 used in this study successfully measures motivation independently from dose or preferred
113 consumption.

114

115 **Striatal DA release inversely reflects a reward's motivational value**

116 To determine how striatal DA release relates to motivation or reward consumption, we took
117 advantage of the daily variation in subjects' performance. Strikingly, DA release to a given fixed
118 reward reflected motivation level (Fig. 3a, b) but not free consumption (Fig. 3c, d). In sessions
119 when mice were more motivated for a given reward, less DA was released in both striatal
120 regions (Fig. 3e, g and Extended Data Fig. 3). Furthermore, group comparisons revealed that
121 mice with higher average motivation levels exhibited lower average DA responses to a fixed
122 reward in both ventral and dorsal striatum (Fig. 3f, h). Thus, DA release reflects both day-to-day
123 and individual-to-individual variability in motivation. In both cases, the lower the motivation, the
124 higher the striatal DA release.

125

126 **Optogenetically-evoked striatal DA release is sensitive to cost.**

127 All of the above results rely on sucrose reward, which is sensitive to circuits associated with
128 taste and satiety. To bypass these circuits and examine the pure motivational effect of striatal
129 DA release, in a separate group of mice we employed optogenetic self-stimulation. Each DAT-
130 Cre mouse received two viral injections: one to deliver either the excitatory opsin ChRMINE or

131 the inert fluorophore mScarlet in DA neurons of the ventral tegmental area (VTA) or substantia
132 nigra pars compacta (SNc), and another to deliver GRAB-DA in the appropriate target in the
133 NAc or DLS. We then implanted a fiber over the NAc or DLS, allowing us to simultaneously
134 stimulate DA inputs and record the resulting DA release. The task was identical as before,
135 except that instead of poking for sucrose, mice poked for optogenetic stimulation of striatal DA
136 release, accompanied by the same light-sound cue (Fig. 4a). As expected, mice learned to poke
137 for DA input stimulation in both the NAc (Fig. 4b) and DLS (Fig. 4d), increasing both the number
138 of rewards (left) and poking accuracy (right) over training. Control mice without opsin did not
139 learn the task for light stimulation in either NAc (Fig. 4c) or DLS (Fig. 4e).

140 Despite using identical light stimulation parameters, as cost increased (i.e. the number of
141 nose pokes required to receive stimulation), optogenetically-evoked DA release in both the NAc
142 (Fig. 4f) and the DLS (Fig. 4h) increased. Control mice, who occasionally nose-poked despite
143 receiving no reward, exhibited no relationship between cost and DA release (Fig. 4g, i).
144 Although these results are consistent with the sucrose experiment (Fig. 1h, i), they were
145 unexpected in that they suggest that the effort put forth by a subject dramatically influences the
146 magnitude of optogenetically-evoked striatal DA release. Thus, we considered an alternative
147 plausible interpretation: that the effect of varying the FR on optogenetic striatal DA release
148 might reflect the longer interval between light stimulation during higher FRs. Perhaps at shorter
149 time intervals, optogenetic stimulation of DA inputs depletes DA and reduces the amount of DA
150 release for subsequent stimulations. However, when we analyzed trials with similar reward
151 intervals at different FRs, the effect held (Extended Data Fig. 4a, b).

152 As a further test of the potential influence of the interval between optogenetic
153 stimulations, we conducted an experiment under anesthesia, in which light stimulations were
154 delivered at different intervals based on the average intervals for each FR in our task. Again, DA
155 release was not influenced by the interval between light stimulations (Extended Data Fig. 4c, d).
156 Finally, we considered if the order of FRs could explain the results; for example due to

157 photobleaching of the sensor over the course of each session. We thus examined how DA
158 release changed over time in a session where optogenetic stimulation was delivered without
159 cost (Extended Data Fig. 4e, f) or with cost held constant (Extended Data Fig. 4g, h). In both
160 cases, we found that DA release did not differ based on whether optogenetic stimulation was
161 delivered at the beginning or the end of the session. Therefore, we conclude that DA release
162 evoked by local optogenetic stimulation of DA inputs in both the NAc and DLS is greatly
163 influenced by the effort put forth to gain that reward, i.e. the sunk cost.

164

165 **Optogenetically-evoked DA release is inversely related to motivation**

166 Analysis of behavioral economic demand curves provides a platform for determining the intrinsic
167 motivational value of striatal DA release. Similar to our experiments using sucrose as the
168 reward, we took advantage of variations in motivation from day to day and mouse to mouse and
169 compared optogenetically-induced DA release in high- versus low-motivation sessions.
170 Consistent with previous results, DA release was greater during low motivation sessions in both
171 the NAc and DLS (Fig. 5a, b and Extended Data Fig. 5). In contrast, the magnitude of free
172 consumption did not affect optogenetic striatal DA release (Fig. 5c, d). The inverse relationship
173 between motivation and optogenetic striatal DA release held both within each subject (Fig 5e, g)
174 and between subjects (Fig. 5f, h). Thus, although DA release was required for animals to learn
175 and perform the task (Fig. 4c, e), greater optogenetic striatal DA release reflected lower
176 motivation.

177

178 **Testing the causal relationship between motivation and striatal DA release**

179 By examining the behavioral variability that routinely occurs within and between subjects during
180 our operant tasks, we provide evidence that the motivation to obtain a natural reward, sucrose,
181 as well as the artificial “reward” of optogenetically-triggered striatal DA release, is inversely
182 correlated with the magnitude of striatal DA release evoked by that reward. Our evidence thus

183 far, however, cannot rule out an indirect or coincidental relationship between motivation and
184 striatal DA release. To test the causal nature of this inverse relationship, we performed two
185 further experiments. First, we sought to manipulate the intrinsic motivation for reward and
186 observe the effect on striatal DA release elicited by that reward. To do so, we trained a new
187 cohort of mice to nosepoke for sucrose reward and compared striatal DA release under two
188 conditions: the standard condition, in which mice lack access to sucrose except for during the
189 behavioral session; and a condition in which the animals had access to sucrose for 30 minutes
190 before each behavioral session. As expected, prefeeding reduced motivation for sucrose (Fig.
191 6a, c) and these sessions were associated with higher striatal DA release in response to the
192 same sucrose reward that was provided during standard sessions (Fig. 6b, d). Thus, a simple
193 “natural” manipulation that reduced motivation for food without impairing task performance
194 resulted in enhanced cued DA release in both the NAc and DLS.

195 Second, we sought to manipulate the DA release elicited by a natural reward and
196 observe the effect on motivation. A cohort of DAT-Cre mice received two viral injections: one to
197 deliver the inhibitory opsin halorhodopsin (NpHR) in DA neurons of the VTA or SNc, and
198 another to deliver GRAB-DA in the appropriate target in the NAc or DLS. We then implanted a
199 fiber over the NAc or DLS, allowing us to simultaneously inhibit DA inputs and record the
200 resulting DA release. Once they recovered from surgery, we trained these mice to nosepoke for
201 sucrose reward in the same paradigm as before. After stabilizing their performance on the
202 behavioral economics task, we used light to inhibit DA release during the 2-sec reward cue on
203 each trial. We found that NpHR stimulation successfully reduced DA release in the NAc (Fig.
204 6e) and DLS (Fig. 6g), and that this manipulation increased motivation for sucrose reward (Fig.
205 6f, h). We conclude that there is a direct, bidirectional relationship between striatal DA release
206 and motivation for natural reward.

207

208

209 **Discussion**

210 Striatal DA release has long been linked to motivation, but most studies of DA and motivation
211 have not recorded DA activity dynamics, and most DA recording studies have not measured
212 motivation. Here we employed concepts from behavioral economics to gauge motivation for
213 both a natural reward, sucrose, and the artificial reward of optogenetically-evoked striatal DA
214 release, all while recording DA transients in the NAc and DLS, two striatal regions implicated in
215 reward processing and operant behavior.

216 Our experiments generated several surprising results that help resolve controversies
217 about the functional roles of striatal DA. First, striatal DA encodes both reward magnitude and
218 sunk cost, which is the cost that has already been paid. Most prior studies have examined DA
219 responses before the cost is paid, finding minimal cost sensitivity⁹⁻¹⁴ even though DA
220 manipulations do appear to affect cost calculations⁵⁻⁸. In addition, influential recent work has
221 debated whether DA activity dynamics better reflect reward value²⁵ or changes in reward
222 value²⁶, but these studies did not modulate cost and thus did not address how DA release
223 signals cost-benefit trade-offs. By varying cost and measuring DA release after the cost is paid,
224 we demonstrate robust cost sensitivity, helping resolve the longstanding debate about whether
225 striatal DA release is primarily important for reward benefit or cost. Our results, consistent with
226 some recent work²⁷, demonstrate that DA release encodes both. These results also provide a
227 neural mechanism for the longstanding psychological observation that we value rewards more if
228 we worked harder for them²⁸.

229 Second, by leveraging individual and temporal variation in motivation, we demonstrate
230 that there is a surprising inverse relationship between transient DA release and motivation. The
231 higher the subject's motivation, the lower the striatal DA release for a fixed reward, and vice
232 versa. This finding may appear to contradict the commonly held notion that DA facilitates
233 motivation^{4,29}. However, it is consistent with the longstanding observation in stimulant addiction
234 that the most severe drug users, who have high motivation to seek and ingest drugs of abuse,

235 exhibit decreases in drug-elicited DA release, which predict the magnitude of drug use and
236 craving^{30,31}. Our findings suggest that chronic drug use, rather than simply triggering a
237 dysphoric, low-DA withdrawal state^{32,33}, may tap into a previously unknown mechanism that
238 modulates striatal DA release depending on motivation. Furthermore, this mechanism appears
239 to work in a qualitatively similar way in both the NAc and the DLS, although the two sites had
240 different release kinetics, perhaps because of greater dopamine transporter expression³⁴ and
241 thus faster uptake³⁵ in dorsal compared to ventral striatum.

242 A third surprising finding was that striatal DA release elicited by optogenetic stimulation
243 of DA inputs was highly context dependent in that it too was influenced by costs, benefits and
244 motivation. Since we only activated DA axons, these results support the importance of local
245 modulation of DA release³⁶⁻³⁹ in addition to input integration at the level of DA cell bodies. They
246 also emphasize that behavioral context can influence the neural consequences of “simple”
247 optogenetic manipulations.

248 Our results support the proposal that striatal DA release encodes costs, benefits and
249 motivation simultaneously but over different time scales. On a trial-by-trial basis, striatal DA
250 release integrates benefit size and sunk cost. Motivation for rewards, in contrast, reflects a state
251 that changes over slower time scales, consistent with recent work on hunger^{40,41}, thirst^{41,42}, and
252 other internal homeostatic drives^{43,44}. The striatal DA signals encoding reward are dampened
253 when motivation is high and augmented when motivation is low. These results are consistent
254 with an accelerator/brake model of DA action in which a high motivational state “releases the
255 brake” such that a lighter push on the accelerator (i.e. smaller DA release) is necessary to
256 initiate actions^{45,46}. Future work that measures the downstream neural consequences of DA
257 release in the striatum and other target regions may reveal how DA not only reflects motivation
258 but also controls it.

259


- 260 1. Schultz, W., Stauffer, W. R. & Lak, A. The phasic dopamine signal maturing: from reward
261 via behavioural activation to formal economic utility. *Curr. Opin. Neurobiol.* **43**, 139–148
262 (2017).
- 263 2. Glimcher, P. W. Understanding dopamine and reinforcement learning: the dopamine reward
264 prediction error hypothesis. *Proc. Natl. Acad. Sci. U.S.A.* **108 Suppl 3**, 15647–15654
265 (2011).
- 266 3. Eshel, N. *et al.* Arithmetic and local circuitry underlying dopamine prediction errors. *Nature*
267 **525**, 243–246 (2015).
- 268 4. Berke, J. D. What does dopamine mean? *Nat Neurosci* **21**, 787–793 (2018).
- 269 5. Salamone, J. D., Correa, M., Yang, J.-H., Rotolo, R. & Presby, R. Dopamine, effort-based
270 choice, and behavioral economics: Basic and translational research. *Front Behav Neurosci*
271 **12**, 52 (2018).
- 272 6. Ishiwari, K., Weber, S. M., Mingote, S., Correa, M. & Salamone, J. D. Accumbens dopamine
273 and the regulation of effort in food-seeking behavior: modulation of work output by different
274 ratio or force requirements. *Behav Brain Res* **151**, 83–91 (2004).
- 275 7. Nunes, E. J. *et al.* Effort-related motivational effects of the VMAT-2 inhibitor tetrabenazine:
276 implications for animal models of the motivational symptoms of depression. *J Neurosci* **33**,
277 19120–19130 (2013).
- 278 8. Salamone, J. D. *et al.* Mesolimbic dopamine and the regulation of motivated behavior. *Curr*
279 *Top Behav Neurosci* **27**, 231–257 (2016).
- 280 9. Walton, M. E. & Bouret, S. What Is the relationship between dopamine and effort? *Trends*
281 *Neurosci* **42**, 79–91 (2019).
- 282 10. Varazzani, C., San-Galli, A., Gilardeau, S. & Bouret, S. Noradrenaline and dopamine
283 neurons in the reward/effort trade-off: a direct electrophysiological comparison in behaving
284 monkeys. *J Neurosci* **35**, 7866–7877 (2015).

- 285 11. Pasquereau, B. & Turner, R. S. Limited encoding of effort by dopamine neurons in a cost-
286 benefit trade-off task. *J Neurosci* **33**, 8288–8300 (2013).
- 287 12. Gan, J. O., Walton, M. E. & Phillips, P. E. M. Dissociable cost and benefit encoding of future
288 rewards by mesolimbic dopamine. *Nat Neurosci* **13**, 25–27 (2010).
- 289 13. Wanat, M. J., Kuhnen, C. M. & Phillips, P. E. M. Delays conferred by escalating costs
290 modulate dopamine release to rewards but not their predictors. *J Neurosci* **30**, 12020–
291 12027 (2010).
- 292 14. Hollon, N. G., Arnold, M. M., Gan, J. O., Walton, M. E. & Phillips, P. E. M. Dopamine-
293 associated cached values are not sufficient as the basis for action selection. *Proc Natl Acad*
294 *Sci U S A* **111**, 18357–18362 (2014).
- 295 15. Samaha, A.-N., Khoo, S. Y.-S., Ferrario, C. R. & Robinson, T. E. Dopamine ‘ups and downs’
296 in addiction revisited. *Trends Neurosci* **44**, 516–526 (2021).
- 297 16. Volkow, N. D., Koob, G. F. & McLellan, A. T. Neurobiologic advances from the brain disease
298 model of addiction. *N Engl J Med* **374**, 363–371 (2016).
- 299 17. Sun, F. *et al.* A genetically encoded fluorescent sensor enables rapid and specific detection
300 of dopamine in flies, fish, and mice. *Cell* **174**, 481–496.e19 (2018).
- 301 18. Volkow, N. D. & Morales, M. The brain on drugs: From reward to addiction. *Cell* **162**, 712–
302 725 (2015).
- 303 19. Graybiel, A. M. & Grafton, S. T. The striatum: where skills and habits meet. *Cold Spring*
304 *Harb Perspect Biol* **7**, a021691 (2015).
- 305 20. Lüscher, C., Robbins, T. W. & Everitt, B. J. The transition to compulsion in addiction. *Nat*
306 *Rev Neurosci* **21**, 247–263 (2020).
- 307 21. Simpson, E. H. & Balsam, P. D. The behavioral neuroscience of motivation: An overview of
308 concepts, measures, and translational applications. *Curr Top Behav Neurosci* **27**, 1–12
309 (2016).

- 310 22. Hursh, S. R. & Silberberg, A. Economic demand and essential value. *Psychol Rev* **115**,
311 186–198 (2008).
- 312 23. Bentzley, B. S., Fender, K. M. & Aston-Jones, G. The behavioral economics of drug self-
313 administration: a review and new analytical approach for within-session procedures.
314 *Psychopharmacology (Berl)* **226**, 113–125 (2013).
- 315 24. R. Hursh, S. Behavioral economics and the analysis of consumption and choice. in *The*
316 *Wiley Blackwell Handbook of Operant and Classical Conditioning* 275–305 (John Wiley &
317 Sons, Ltd, 2014). doi:10.1002/9781118468135.ch12.
- 318 25. Mohebi, A. *et al.* Dissociable dopamine dynamics for learning and motivation. *Nature* **570**,
319 65–70 (2019).
- 320 26. Kim, H. R. *et al.* A unified framework for dopamine signals across timescales. *Cell* **183**,
321 1600-1616.e25 (2020).
- 322 27. Tanaka, S., O’Doherty, J. P. & Sakagami, M. The cost of obtaining rewards enhances the
323 reward prediction error signal of midbrain dopamine neurons. *Nat Commun* **10**, 3674 (2019).
- 324 28. Inzlicht, M., Shenhav, A. & Olivola, C. Y. The effort paradox: Effort is both costly and valued.
325 *Trends Cogn Sci* **22**, 337–349 (2018).
- 326 29. Salamone, J. D. & Correa, M. The mysterious motivational functions of mesolimbic
327 dopamine. *Neuron* **76**, 470–485 (2012).
- 328 30. Ashok, A. H., Mizuno, Y., Volkow, N. D. & Howes, O. D. Association of stimulant use with
329 dopaminergic alterations in users of cocaine, amphetamine, or methamphetamine: A
330 Systematic Review and Meta-analysis. *JAMA Psychiatry* **74**, 511–519 (2017).
- 331 31. Willuhn, I., Burgeno, L. M., Groblewski, P. A. & Phillips, P. E. M. Excessive cocaine use
332 results from decreased phasic dopamine signaling in the striatum. *Nat Neurosci* **17**, 704–
333 709 (2014).
- 334 32. Koob, G. F. & Le Moal, M. Drug addiction, dysregulation of reward, and allostasis.
335 *Neuropsychopharmacology* **24**, 97–129 (2001).

- 336 33. Dackis, C. A. & Gold, M. S. New concepts in cocaine addiction: the dopamine depletion
337 hypothesis. *Neurosci Biobehav Rev* **9**, 469–477 (1985).
- 338 34. Freed, C. *et al.* Dopamine transporter immunoreactivity in rat brain. *Journal of Comparative*
339 *Neurology* **359**, 340–349 (1995).
- 340 35. Cragg, S. J., Hille, C. J. & Greenfield, S. A. Dopamine release and uptake dynamics within
341 nonhuman primate striatum in vitro. *J. Neurosci.* **20**, 8209–8217 (2000).
- 342 36. Liu, C. & Kaeser, P. S. Mechanisms and regulation of dopamine release. *Curr Opin*
343 *Neurobiol* **57**, 46–53 (2019).
- 344 37. Liu, C. *et al.* An action potential initiation mechanism in distal axons for the control of
345 dopamine release. *Science* **375**, 1378–1385 (2022).
- 346 38. Kramer, P. F., Twedell, E. L., Shin, J. H., Zhang, R. & Khaliq, Z. M. Axonal mechanisms
347 mediating γ -aminobutyric acid receptor type A (GABA-A) inhibition of striatal dopamine
348 release. *Elife* **9**, e55729 (2020).
- 349 39. Holly, E. N., Davatolhagh, M. F., España, R. A. & Fuccillo, M. V. Striatal low-threshold
350 spiking interneurons locally gate dopamine. *Curr Biol* **31**, 4139–4147.e6 (2021).
- 351 40. Burgess, C. R. *et al.* Hunger-dependent enhancement of food cue responses in mouse
352 postrhinal cortex and lateral amygdala. *Neuron* **91**, 1154–1169 (2016).
- 353 41. Grove, J. C. R. *et al.* Dopamine subsystems that track internal states. *Nature* (2022)
354 doi:10.1038/s41586-022-04954-0.
- 355 42. Allen, W. E. *et al.* Thirst-associated preoptic neurons encode an aversive motivational drive.
356 *Science* **357**, 1149–1155 (2017).
- 357 43. Steinmetz, N. A., Zatka-Haas, P., Carandini, M. & Harris, K. D. Distributed coding of choice,
358 action and engagement across the mouse brain. *Nature* **576**, 266–273 (2019).
- 359 44. Pettit, N. L., Yuan, X. C. & Harvey, C. D. Hippocampal place codes are gated by behavioral
360 engagement. *Nat Neurosci* **25**, 561–566 (2022).

- 361 45. Beeler, J. A. & Mourra, D. To do or not to do: Dopamine, affordability and the economics of
362 opportunity. *Front Integr Neurosci* **12**, 6 (2018).
- 363 46. Soutschek, A., Jetter, A. & Tobler, P. N. Toward a unifying account of dopamine's role in
364 cost-benefit decision making. *Biological Psychiatry Global Open Science* (2022)
365 doi:10.1016/j.bpsgos.2022.02.010.
366



368 **Fig. 1: DA release in NAc and DLS encodes both benefit and cost.**

369 **a**, Experimental timeline and schematic of behavioral task. FR, fixed ratio. **b**, Left, number of
370 rewards earned each day during FR1 training (Friedman test, Friedman statistic=22.4,
371 $P=0.0002$; $n=12$). Right, latency to enter reward port after light-sound cue (Friedman test,
372 Friedman statistic=16.3, $P=0.0026$; $n=12$). **c**, Left, sucrose consumed per session as a function
373 of the quantity and concentration of each reward (Mixed-effects model, fixed effect of quantity,
374 $F_{1,11}=17.9$, $P=0.0014$; fixed effect of concentration, $F_{1,11}=176$, $P<0.0001$; Tukey-corrected
375 multiple comparisons: $10\mu\text{L-5\%}$ vs $10\mu\text{L-32\%}$, $P<0.0001$; $10\mu\text{L-5\%}$ vs $25\mu\text{L-5\%}$, $P=0.0029$;
376 $10\mu\text{L-32\%}$ vs $25\mu\text{L-32\%}$, $P=0.024$; $25\mu\text{L-5\%}$ vs $25\mu\text{L-32\%}$, $P=0.0001$; $n=12$). Right, average
377 number of rewards earned for each FR (Friedman test, Friedman statistic=47.6, $P<0.0001$;
378 $n=12$). **d-i**, Left, Z-scored photometry traces of GRAB-DA fluorescence aligned to reward-
379 predicting cues. Right, area under the curve (AUC) of Z-scored photometry traces from 0 to 4s
380 after cue onset as a function of sucrose concentration (**d**: Wilcoxon matched-pairs signed rank
381 test, $W=50$, $P=0.024$; $n=12$; **e**: Wilcoxon matched-pairs signed rank test, $W=64$, $P=0.002$; $n=12$),
382 sucrose quantity (**f**: Wilcoxon matched-pairs signed rank test, $W=62$, $P=0.003$; $n=12$, **g**:
383 Wilcoxon matched-pairs signed rank test, $W=54$, $P=0.014$; $n=12$) or FR (**h**: Friedman test,
384 Friedman statistic=15.2, $P=0.0043$; $n=12$, **i**: Friedman test, Friedman statistic=24.2, $P<0.0001$;
385 $n=12$). **d, f, h**, recordings in the NAc. **e, g, i**, recordings in the DLS. * $P<0.05$, ** $P<0.01$,
386 *** $P<0.001$. Error bars denote s.e.m.

387

388


389

390

391

392

393



394

395 **Fig. 2: Economic demand curves dissociate consumption from motivation.**

396 **a**, Schematic demand curves plotting reward consumption as a function of cost. Shallower slope

397 denotes higher motivation. **b**, Motivation parameter ($1/\alpha$) on consecutive days with the same

398 reward (Spearman correlation, $r=0.86$, $P<0.0001$; $n=44$ sessions from 12 mice). **c**, Free


399 consumption parameter (Q_0) on consecutive days with the same reward (Spearman correlation,

400 $r=0.82$, $P<0.0001$; $n=44$ sessions from 12 mice). **d**, Average motivation as a function of sucrose

401 quantity and concentration (Mixed-effects model, fixed effect of quantity, $F_{1,11}=3.95$, $P=0.073$;

402 fixed effect of concentration, $F_{1,11}=0.36$, $P=0.56$; $n=12$). **e**, Average free consumption as a

403 function of sucrose quantity and concentration (Mixed-effects model, fixed effect of quantity,
404 $F_{1,11}=26.3$, $P=0.0003$; fixed effect of concentration, $F_{1,11}=9.88$, $P=0.0093$; Tukey-corrected
405 multiple comparisons: 10 μ L-5% vs 10 μ L-32%, $P=0.025$; 10 μ L-5% vs 25 μ L-5%, $P=0.0003$;
406 10 μ L-32% vs 25 μ L-32%, $P=0.0003$; 25 μ L-5% vs 25 μ L-32%, $P=0.025$; $n=12$). **f**, Left,
407 representative demand curves from a single mouse exposed to four rewards. Right, the same
408 demand curves, now normalized by free consumption. **g**, Schematic of FR5 shock task. **h**, **i**,
409 Previously-measured motivation (**h**: Spearman correlation, $r=0.79$, $P=0.003$; $n=12$) and free
410 consumption (**i**: Spearman correlation, $r=0.38$, $P=0.22$; $n=12$) versus number of shocks
411 tolerated. NS, not significant; * $P<0.05$, *** $P<0.001$. Error bars denote s.e.m.



412

413 **Fig. 3: Striatal DA release inversely reflects a reward's motivational value.**

414 **a-d**, Left, Z-scored photometry traces of GRAB-DA fluorescence in the NAc (**a**, **c**) or DLS (**b**, **d**)

415 aligned to reward-predicting cues. Right, AUC of Z-scored photometry traces from 0 to 4s after

416 cue onset as a function of motivation (**a**: Mann-Whitney test, $U=475$, $P=0.001$; $n=81$ sessions


417 from 12 mice; **b**: Mann-Whitney test, $U=735$, $P=0.0049$; $n=94$ sessions from 12 mice) or free

418 consumption (**c**: Mann-Whitney test, $U=775$, $P=0.68$; $n=81$ sessions from 12 mice, **d**: Mann-

419 Whitney test, $U=978$, $P=0.34$, $n=94$ sessions from 12 mice). **e**, **g**, Motivation versus the AUC of

420 cue-evoked GRAB-DA signal in the NAc (**e**) or DLS (**g**) for individual mice (each colored line

421 denotes one mouse). **f**, **h**, Average motivation for 10 μ L, 32% sucrose reward versus the
422 average GRAB-DA signal for the cue predicting that reward in the NAc (**f**: Spearman correlation,
423 $r = -0.62$, $P=0.048$; $n=11$) or DLS (**h**: Spearman correlation, $r = -0.64$, $P=0.028$; $n=12$). NS, not
424 significant; * $P<0.05$, ** $P<0.01$, *** $P<0.001$. Error bars denote s.e.m.



425

426 **Fig. 4: Optogenetically-evoked striatal DA release is sensitive to sunk cost.**

427 **a**, Schematic of optogenetic self-stimulation task. **b-e**, Number of rewards earned each day (left)

428 and fraction of nosepokes in the active poke (right) during FR1 training in mice with ChRMINE in

429 the NAc (**b**: rewards, Friedman test, Friedman statistic=31.9, $P < 0.0001$; $n = 9$; accuracy,

430 Friedman test, Friedman statistic=15.3, $P = 0.0042$; $n = 9$) or DLS (**d**: rewards, Friedman test,

431 Friedman statistic=31.2, $P < 0.0001$; $n = 14$; accuracy, Friedman test, Friedman statistic=19.8,


432 $P = 0.0006$; $n = 14$), or control mice with mScarlet in the NAc (**c**: rewards, Friedman test, Friedman

433 statistic=9.01, $P = 0.061$; $n = 5$; accuracy, Friedman test, Friedman statistic=9.12, $P = 0.058$; $n = 5$)

434 or DLS (**e**: rewards, Friedman test, Friedman statistic=2.87, $P = 0.58$; $n = 5$; accuracy, Friedman

435 test, Friedman statistic=1.92, $P = 0.75$; $n = 5$). **f-i**, Left, Z-scored photometry traces of GRAB-DA

436 fluorescence in the NAc (**f**, **g**) or DLS (**h**, **i**) aligned to optogenetic stimulation in ChRMINE mice
437 (**f**, **h**) or mScarlet controls (**g**, **i**). Right, AUC of Z-scored photometry traces from 0 to 10s after
438 stimulation onset as a function of FR in mice with ChRMINE in the NAc (**f**: Friedman test,
439 Friedman statistic=20.0, $P=0.0005$; $n=5$) or DLS (**h**: Friedman test, Friedman statistic=32.4,
440 $P<0.0001$; $n=10$) or control mice with mScarlet in the NAc (**g**: Mixed-effects model, $F_{3,12}=0.44$,
441 $P=0.44$; $n=5$) or DLS (**i**: Mixed-effects model, $F_{3,8}=0.81$, $P=0.52$; $n=5$). NS, not significant;
442 $*P<0.05$, $**P<0.01$, $***P<0.001$. Error bars denote s.e.m.



443

444 **Fig. 5: Optogenetically-evoked striatal DA release is inversely related to motivation.**

445 **a-d**, Left, Z-scored photometry traces of GRAB-DA fluorescence in the NAc (**a**, **c**) or DLS (**b**, **d**)

446 aligned to optogenetic stimulation. Right, AUC of Z-scored photometry traces from 0 to 4s after

447 stimulation onset as a function of motivation (**a**: Mann-Whitney test, $U=798$, $P=0.0061$; $n=97$


448 sessions from 9 mice; **b**: Mann-Whitney test, $U=2293$, $P=0.0038$; $n=158$ sessions from 14 mice)

449 or free consumption (**c**: Mann-Whitney test, $U=1085$, $P=0.52$; $n=97$ sessions from 9 mice; **d**:

450 Mann-Whitney test, $U=2812$, $P=0.29$; $n=158$ sessions from 14 mice). **e**, **g**, Motivation versus the

451 AUC of stimulation-evoked GRAB-DA signal in the NAc (**e**) or DLS (**g**) for individual mice (each

452 colored line denotes one mouse). **f**, **h**, Average motivation for optogenetic stimulation reward
453 versus the average GRAB-DA signal for that reward in the NAc (**f**: Spearman correlation, $r = -$
454 1.0 , $P=0.017$; $n=5$) or DLS (**h**: Spearman correlation, $r = -0.86$, $P=0.0006$; $n=12$). NS, not
455 significant; $*P<0.05$, $**P<0.01$, $***P<0.001$. Error bars denote s.e.m.



456

457 **Fig. 6: Bidirectional relationship between motivation and striatal DA release.**

458 **a, c**, Motivation for the same sucrose reward after 24-hr sucrose deprivation versus 30-min
 459 unlimited sucrose consumption for mice with fiber implants in the NAc (**a**: Wilcoxon matched-
 460 pairs signed rank test, $W=-43$, $P=0.0078$; $n=9$) or DLS (**c**: Wilcoxon matched-pairs signed rank
 461 test, $W=-28$, $P=0.016$; $n=7$). **b, d**, Left, Z-scored photometry traces of GRAB-DA fluorescence in
 462 the NAc (**b**) or DLS (**d**) aligned to reward-predicting cues. Right, AUC of Z-scored photometry
 463 traces from 0 to 4s after cue onset in standard versus pre-fed conditions in the NAc (**b**:
 464 Wilcoxon matched-pairs signed rank test, $W=34$, $P=0.016$; $n=8$) or DLS (**d**: Wilcoxon matched-
 465 pairs signed rank test, $W=28$, $P=0.016$; $n=7$). **e, g**, Left, Z-scored photometry traces of GRAB-
 466 DA fluorescence in the NAc (**e**) or DLS (**g**) aligned to cue onset in the optogenetic inhibition

467 experiment. Right, AUC of Z-scored photometry traces from 0 to 4 s after cue onset as a
468 function of whether inhibitory optogenetic stimulation was delivered during the cue in the NAc
469 (**e**: Wilcoxon matched-pairs signed rank test, $W=-21$, $P=0.031$; $n=6$) or DLS (**g**: Wilcoxon
470 matched-pairs signed rank test, $W=-21$, $P=0.031$; $n=6$). **f**, **h**, Motivation in sessions with or
471 without optogenetic inhibition in the NAc (**f**: Wilcoxon matched-pairs signed rank test, $W=21$,
472 $P=0.031$; $n=6$) or DLS (**h**: Wilcoxon matched-pairs signed rank test, $W=21$, $P=0.031$; $n=6$).
473 $*P<0.05$, $**P<0.01$.

474 **METHODS**

475 **Mice**

476 Female and male mice, first-generation offspring of female CD-1 mice (Charles River, strain 22)
477 and either male C57BL/6J mice (Jackson Laboratory, strain #664) or male DAT:IRES-Cre mice
478 on a C57BL/6J background (Jackson Laboratory, strain #006660) were used as experimental
479 subjects. This CD-1/C57 hybrid strategy was chosen to facilitate related research on aggressive
480 behavior as previously validated^{47,48}. All transgenic animals used in these experiments were
481 genotyped and found to be heterozygous for Cre recombinase. Mice were group-housed before
482 surgical procedures. After surgery, males were single-housed to reduce aggression within a
483 cage. Behavioral experiments were conducted during the dark cycle (lights off at 09:00, on at
484 21:00) when mice were 10-24 weeks old. Mice were maintained under food restriction for all
485 behavioral experiments (>80% body weight from baseline ad libitum period). All procedures
486 complied with the animal care standards set forth by the National Institutes of Health (NIH) and
487 were approved by the Stanford University Administrative Panel on Laboratory Animal Care and
488 Administrative Panel of Biosafety.

489

490 **Stereotactic injections and viruses**

491 Mice (8-12 weeks of age) were anesthetized with isoflurane (5% induction, 1-2% maintenance).
492 Meloxicam (5 mg/kg) was administered subcutaneously at the start of surgery and 24 and 48
493 hours after. Heads were fixed on a Kopf stereotaxic apparatus, a small incision was made in the
494 scalp, and burr holes were drilled in the skull over the sites of injection. The following bregma
495 coordinates were used: VTA, -3.1 mm anteroposterior (AP), \pm 0.7 mm mediolateral (ML), 4.2 mm
496 dorsoventral (DV) from dura; SNc, -3.1 mm AP, \pm 1.0 mm ML, 4.3 mm DV; NAc, 1.5 mm AP,
497 \pm 0.9 mm ML, 4.2 mm DV; DLS, 0.8 mm AP, \pm 2.3 ML, 3.1 mm DV. Microliter syringes (Hamilton)
498 were lowered to the specified depth from the dura and used to inject 0.5 μ L of virus solution at a
499 flow rate of 0.1-0.25 μ L min⁻¹. For experiments with two viral injections in the same location

500 (e.g., for optogenetic stimulation and photometry recording), a total of 1 μ L mixed solution was
501 injected. Borosilicate optic fibers for photometry and/or optogenetic stimulation with 400- μ m
502 diameter and numerical aperture 0.66 (Doric) were implanted directly above the striatal virus
503 injection site, ipsilateral to the midbrain virus injection site, and secured to the skull using light-
504 cured dental adhesive cement (Geristore A&B paste, DenMat). For the cohort with recordings in
505 both NAc and DLS (Extended Data Fig. 1a), the NAc and DLS fibers were implanted in different
506 hemispheres. For other cohorts, the hemisphere was counterbalanced between mice.

507 Adeno-associated viruses (AAVs) used for stereotactic injections were AAV9-hSyn-
508 DA2m (DA4.4, WZ Biosciences), AAV-8-EF1 α -DIO-ChRmine-mScarlet-WPRE (Stanford Gene
509 Vector and Virus Core), AAV-8-EF1 α -DIO-mScarlet-WPRE (Stanford Gene Vector and Virus
510 Core), and AAV-DJ-EF1 α -DIO-NpHR3.0-mCherry (Stanford Gene Vector and Virus Core). AAV
511 titres ranged from 1×10^{12} to 2×10^{13} gc ml⁻¹.

512

513 **Optogenetic manipulations**

514 For photostimulation of ChRMINE or NpHR, optical implants were connected to a 625nm LED
515 light source (Prizmatix) via a plastic fiber (1mm diameter, NA 0.63) and a fiber optic rotary joint
516 (Doric). In an attempt to mimic DA release dynamics for natural reward, we used slightly
517 different sets of ChRMINE stimulation parameters for NAc and DLS. For the data presented in
518 Fig. 4 and Extended Data Fig. 4, NAc stimulation was kept at 5 s, 20 Hz and 6mW, while DLS
519 stimulation was kept at 0.5 s, 20 Hz and 10 mW, all with a pulse width of 10 ms. On other
520 demand sessions (data shown in Fig. 5 and Extended Data Fig. 5), frequency was varied from
521 1-20 Hz, duration from 0.5-30 seconds and power from 3-10 mW, while pulse width was kept at
522 10ms. We found that these parameter changes did not systematically affect either motivation or
523 DA release in the demand task, and thus we combined all sessions for the analyses in Fig. 5a-
524 d, e, g and Extended Data Fig. 5. For NpHR stimulation, light was turned on (10 mW at fiber tip)
525 for 2 s, only during the cue period.

526

527 **Fiber photometry**

528 For photometry recordings, optical implants were connected to low-autofluorescence patch
529 cords (400 μm diameter, 0.57 numerical aperture, Doric) via a ceramic sleeve (Doric). Signals
530 then passed through a fiber optic rotary joint (Doric) before filtering through a fluorescence mini
531 cube (Doric) and ultimately reaching a femtowatt photodetector (2151; Newport). Frequency-
532 modulated blue (465 nm) and UV (405 nm) LEDs (Doric) were used to stimulate GRAB-DA
533 emission and control signals through the same fibers. Blue LED power was adjusted to $\sim 30\mu\text{W}$
534 at the fiber tip to ensure that the photodetector was not being saturated. Digital signals were
535 sampled at 1.0173 kHz, demodulated, lock-in amplified, and recorded by a real-time signal
536 processor (RZ5P, Tucker-Davis Technologies) using Synapse software (Tucker-Davis
537 Technologies). Synchronized behavioral events from the Med Associates boxes were collected
538 directly into the RZ5P digital input ports. To reduce any confounds from photobleaching,
539 animals were recorded for about 5 min before behavioral testing began.

540

541 **Behavioral training**

542 Behavioral training began at least 2 weeks after virus injections. For the first 2 days, mice were
543 tethered to the fiber optic patch cord and allowed to explore the behavioral chambers (Med
544 Associates) for 30 minutes. Each chamber had a speaker for white noise and three identical
545 nose ports, each with an associated light and an infrared emitter-sensor to measure port entry
546 times. The central nose port was defined as the reward port and was equipped to receive 10-25
547 μL sucrose (at 5% or 32% concentration) from a syringe pump.

548 After habituation to the chamber and tether, mice were exposed to 2 days of a Pavlovian
549 task, in which rewards were delivered at random intervals between 25 and 35 s for 30 min. Each
550 reward was delivered in tandem with a 2-s light-sound cue (white noise and central port light),
551 with the goal that the mice would begin to associate the cue with reward delivery. Mice were

552 then trained on FR1, meaning that a single poke in the active port was required for reward
553 delivery. The identity of the active port (left or right) was kept consistent for each mouse, but
554 counterbalanced between mice. For at least the first 3 days, or until the mice achieved 10
555 rewards per session, the active port was baited with a fruit loop to encourage the mice to
556 explore that port. The bait was then removed and mice continued with at least five days of FR1,
557 or until the number of rewards per session remained within 20% for 3 consecutive days. The
558 training data in Fig. 1 derives from these unbaited FR1 sessions. Mice were then trained on FR5
559 until they achieved at least 10 rewards per session for 3 consecutive days, and then moved
560 onto demand sessions (see below).

561 Training for optogenetic self-stimulation (Figs. 4-5) was identical, except instead of
562 sucrose reward being delivered at the time of the light-sound cue, mice received optogenetic
563 stimulation. Recording data from the optogenetic Pavlovian and FR5 sessions are shown in
564 Extended Data Fig. 4e-g.

565 Male and female mice were used in approximately equal numbers in all behavioral tasks
566 and there was no sex difference in any experimental condition. Subject mice were excluded
567 from the analysis (less than 5% of 86 total) if they did not reach behavioral criteria or if on the
568 basis of histological analysis, they had: (1) off-target transgene expression; (2) weak transgene
569 expression; or (3) inaccurate implant placement.

570

571 **Demand sessions**

572 During demand sessions, mice experienced 5 consecutive 10-min blocks, each with a different
573 FR, in the following order: FR46, FR21, FR10, FR5, FR1. This order was chosen after extensive
574 piloting showed that random presentation of FRs produced erratic responses, which is
575 consistent with prior work⁴⁹. We chose not to use an ascending order of FRs to reduce the
576 chance of satiety from rapid consumption of rewards early in a session. In control experiments,

577 we confirmed that the demand curves extracted from single sessions were similar to those
578 extracted over 5 days, with a different FR presented on each day (data not shown).

579 On each trial, mice poked the required number of times in the active port and on the last
580 required poke, the 2-s light-sound cue was presented. In the sucrose task, cue onset was
581 simultaneous with sucrose delivery into the central port. After the cue ended and mice entered
582 the central port to consume the sucrose, a light turned on in the active port denoting that
583 another trial had begun and mice were free to poke again. In the optogenetic task, cue onset
584 was simultaneous with LED stimulation. As soon as both LED stimulation and the cue had
585 ended, a light turned on in the active port denoting that another trial had begun and mice were
586 free to poke again.

587 We continued demand sessions for a single reward type for at least 2 days, or until the
588 alpha parameter achieved stability within 20%. We then switched the reward type (i.e., sucrose
589 volume or concentration or LED power, frequency or duration). The order of reward types was
590 counterbalanced between mice.

591

592 **Shock experiment**

593 After mice had completed the sucrose demand sessions, they returned to the standard FR5 task
594 for one day, and on the next day performed the FR5-shock task. In this task, mice received
595 reward as usual after 5 pokes, but on a randomly-selected 30% of trials, they also received a
596 mild shock (0.2 mA, 0.5 s) through an electrified grid floor (Med Associates).

597

598 **Prefeeding experiment**

599 Mice were trained to stability on the demand task as above, having access to sucrose only
600 during the task itself. They then underwent a prefeeding procedure as follows: 30 min before the
601 session, they were given access to 1.5 mL sucrose in their home cage. If they finished the
602 sucrose, they were given another 0.5 mL, and if they finished that, they were given another 0.5

603 mL, and so on until the session was scheduled to begin. We found that this graded approach
604 maintained the subjects' motivation to perform the task better than providing unlimited sucrose
605 (data not shown).

606

607 **Optogenetic inhibition experiment**

608 DAT-Cre mice were injected with Cre-dependent NpHR3.0 in the VTA or SNc and GRAB-DA in
609 the NAc or DLS, respectively, and a fiber was implanted above the striatal target. After 2 weeks
610 of recovery, mice were trained on the sucrose demand sessions as usual, without any
611 optogenetic stimulation, until the alpha parameter stabilized within 20% on 2 consecutive days.
612 They then underwent inhibition experiments, which were identical except for the addition of 2-s
613 red light stimulation during each cue period. Mice underwent at least 3 optogenetic sessions,
614 until the alpha parameter stabilized within 20%. Data in Fig. 6e-h are derived from the last 2
615 days of standard performance and the last 2 days of optogenetic stimulation, when performance
616 was stable.

617

618 **Alternating FR experiment**

619 Mice were trained on the sucrose FR1 and FR5 tasks as usual and were then split into two
620 cohorts. One cohort performed a task with 4, 10-min blocks in the following order: FR10, then
621 FR1, then FR1, then FR10. The other cohort performed a task with the following order: FR1,
622 then FR10, then FR10, then FR1. Each cohort repeated the task on 2 consecutive days and the
623 data in Extended Data Fig. 2e-h comes from the average of the 2 days. We designed these
624 tasks to compare cued DA responses on consecutive blocks as a function of FR order (1 before
625 10 or 10 before 1). Our design allows for both within-subject comparisons (analyzing the first 2
626 blocks vs the last 2 blocks of a session) and between-subject comparisons (analyzing the first 2
627 blocks in one cohort vs the other cohort).

628

629 **Anesthetized recording experiment**

630 DAT-Cre mice were injected with Cre-dependent ChRMINE in the VTA or SNc and GRAB-DA in
631 the NAc or DLS, respectively, and a fiber was implanted above the striatal target. After 2 weeks
632 of recovery, mice were anesthetized with ketamine (60 mg/kg) and dexmedetomidine (0.6
633 mg/kg) through intraperitoneal injection, placed on a heating pad to maintain body temperature,
634 and tethered to the photometry setup as usual. We then recorded GRAB-DA signals while mice
635 received 60 optogenetic stimulations (for NAc: 5 s, 20 Hz, 6mW; for DLS: 0.5 s, 20 Hz, 10 mW)
636 at intervals chosen at random from the following options: 5 s, 10 s, 20 s, 30 s, 70 s and 120 s.
637 These intervals were chosen because they were the average intervals between rewards during
638 the optogenetic demand task (NAc: 5s, 10s, 30s, 70s, 120s; DLS: 10s, 20s, 30s, 70s, 120s).

639

640 **Immunohistochemistry**

641 Mice were perfused with 4% PFA and brains were removed and post-fixed overnight at 4 °C.
642 70–75- μ m coronal sections were prepared on a vibratome and free-floating sections were
643 processed for immunohistochemistry. After three 10-min washes in PBS on a shaker, the tissue
644 was incubated with blocking solution (5% normal goat serum and 0.3% Triton X-100 in PBS) for
645 1 hour and then incubated in primary antibodies overnight at 4 °C on a shaker. The primary
646 antibodies used were: rat mCherry monoclonal antibody 1:1,000 (Invitrogen, M11217)
647 and chicken anti-GFP 1:1,000 (Aves labs, GFP-1020). After three washes of 10 min in PBS,
648 secondary antibodies were added and incubated for 2 h at room temperature on a shaker. The
649 secondary antibodies used were: goat anti-rat Alexa Fluor 594 1:750 (Invitrogen, A11007) and
650 goat anti-chicken Alexa Fluor 488 1:750 (Abcam, ab150169). After three more washes, the
651 slices were mounted with DAPI Fluoromount-G mounting medium (SouthernBiotech) onto
652 microscopy slides for visualization at 4x using a Keyence BZ-X810 slide scanner (Keyence Plan
653 Apo Chromat 4 \times objective, NA 0.20, filter cubes: DAPI, GFP, TRITC, wavelength: 430–741 nm,
654 bit depth of images: 14 bit).

655

656 **Data analysis**

657 Custom scripts in MATLAB (MathWorks) were used for signal processing. Signals were down-
658 sampled 10x, underwent Loess smoothing (window size = 30 ms) to reduce high-frequency
659 noise, and analyzed in 16-s windows around each cue delivery. Z-scores of the fluorescence for
660 each trial were calculated based on the mean and standard deviation of the local baseline signal
661 before each cue (-8 to -4 s before cue onset). Trials were combined into a single session
662 average, and sessions were then averaged together for a single mouse. All photometry figures
663 in the manuscript show the mean and standard error of the photometry signal across mice, a
664 more conservative approach than using the trial- or session-average. To quantify total DA
665 release, area under the curve was calculated using trapezoidal numerical integration on the Z-
666 scores for the windows defined in the figure legends. To compare high- vs low-motivation
667 sessions (Fig. 3a-d; Fig. 5a-d), we performed a median split by the alpha parameter.

668 To minimize bleaching confounds, we removed the first ~5 minutes of each recording,
669 when the steepest bleaching was likely to occur. We also analyzed short windows of data with
670 local baselines, avoiding any analysis of longer-timescale changes, which are more likely to be
671 confounded by bleaching or other gradual changes (e.g., slight adjustments in the connection
672 between the implant and the patch cord). In addition, we took the approach reported by Sych et
673 al⁵⁰ and examined simultaneously-recorded control signals (405 nm), which we found to be flat
674 or slightly negative traces with substantially lower amplitude than what we observed with the
675 experimental excitation (465 nm). Although this analysis is imperfect because 405 nm is not the
676 isosbestic point for GRAB-DA⁵¹, the result implies that motion artifacts, bleaching, or other
677 intrinsic, non-DA dependent signal changes could not have made a major contribution to our
678 results.

679 Finally, we repeated all of our analyses using two methods to correct for bleaching, and
680 our results held regardless of method. In the first method, the entire session was debleached

681 according to the iterative method outlined by Bruno et al⁵², which calculates the $\Delta F/F$ in short
682 moving windows, centers and normalizes these windows, and then repeats these calculations
683 for 100 temporally-offset windows in the same session. The final debleached signal is the
684 average of the 100 iterations. In the second method, we used polynomial curve fitting to fit the
685 control 405 signal to the experimental 465 signal, then subtracted the fitted 405 signal from the
686 experimental signal, and based all subsequent analyses on this subtracted signal. We chose not
687 to complete this as our primary analysis because 405 nm is not the isosbestic point for GRAB-
688 DA and because we observed that the bleaching rates for the two signals were often poorly
689 aligned.

690 To produce demand curves, we used the nonlinear least squares method to fit
691 behavioral data from each session to the following exponential equation²²:

$$692 \quad \ln(Q) = \ln(Q_0) + k(e^{-\alpha Q_0 C} - 1)$$

693 where Q is the number of rewards earned in a block, C is the cost (FR) of each reward for that
694 block, and k is a constant that specifies the range of Q (here we set $k = 3.2$). From these fits we
695 extracted estimates of 2 parameters: Q_0 , or the preferred consumption at no cost; and α , the
696 slope or elasticity of the curve. We then converted α to our measure of motivation, also known
697 as essential value, with the following equation²⁴:

$$698 \quad \text{Motivation} = 1/(100 * \alpha * k^{1.5})$$

699 As in prior work²³, goodness of fit was calculated with R^2 and sessions were included in
700 analysis only when $R^2 > 0.3$. The median R^2 ranged between 0.88 and 0.94 for the different
701 behavioral cohorts.

702

703 **Statistical methods and reproducibility**

704 All experiments were performed without knowledge of the virus that had been injected or the
705 transgene being expressed, and were analyzed without knowledge of the specific manipulation
706 each mouse had undergone. No statistical methods were used to predetermine sample size,

707 which was based on previous experience with the variance of the assays. All data were tested
708 for normality of sample distributions and when violated, non-parametric statistical tests were
709 used. Friedman's test was used to compare three or more matched groups (e.g., DA response
710 from the same animals across 5 FRs). If individual data points were missing from these
711 matched comparisons, mixed-effects models were used instead. Mixed-effects models were
712 also used when examining the effects of multiple fixed effects (e.g., sucrose quantity and
713 concentration) accounting for the random effect of subject. In these cases, the significance of
714 the fixed effects was reported in the figure legends and if there were significant fixed effects,
715 Tukey-corrected post-hoc comparisons were reported with asterisks in the figures. Wilcoxon
716 matched-pairs signed rank tests were used to compare two paired groups (e.g., DA response
717 from the same animals across two concentrations of sucrose). Spearman correlations were
718 used to measure the association between two independently-measured observations (e.g.,
719 motivation on consecutive days). Mann-Whitney tests were used to compare two unmatched
720 groups (e.g., DA response in high-motivation vs low-motivation sessions). Kruskal-Wallis tests
721 were used to compare three or more unmatched groups (e.g., DA responses from trials with
722 different inter-reward intervals). All statistical tests were two-sided and performed in MATLAB
723 (Mathworks) or Prism (GraphPad). NS, not significant. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. In all
724 figures, data are shown as mean \pm s.e.m.

725

726 **References**

- 727 47. Golden, S. A. *et al.* Persistent conditioned place preference to aggression experience in
728 adult male sexually-experienced CD-1 mice. *Genes Brain Behav.* **16**, 44–55 (2017).
- 729 48. Golden, S. A. *et al.* Nucleus Accumbens Drd1-Expressing Neurons Control Aggression Self-
730 Administration and Aggression Seeking in Mice. *J. Neurosci.* **39**, 2482–2496 (2019).

- 731 49. Schelp, S. A. *et al.* A transient dopamine signal encodes subjective value and causally
732 influences demand in an economic context. *Proc Natl Acad Sci U S A* **114**, E11303–E11312
733 (2017).
- 734 50. Sych, Y., Chernysheva, M., Sumanovski, L. T. & Helmchen, F. High-density multi-fiber
735 photometry for studying large-scale brain circuit dynamics. *Nat Methods* **16**, 553–560
736 (2019).
- 737 51. Sun, F. *et al.* Next-generation GRAB sensors for monitoring dopaminergic activity in vivo.
738 *Nat Methods* **17**, 1156–1166 (2020).
- 739 52. Bruno, C. A. *et al.* pMAT: An open-source software suite for the analysis of fiber photometry
740 data. *Pharmacology Biochemistry and Behavior* **201**, 173093 (2021).
- 741

742 **ACKNOWLEDGMENTS**

743 We thank Marija Kamceva, Zihui Zhang, Anjali Temal, Ariana Rodrigues and members of the
744 STAAR and Malenka labs for technical assistance and discussions. The Stanford Gene Vector
745 and Virus Core provided reagents. This work was supported by philanthropic funds donated to
746 the Nancy Pritzker Laboratory at Stanford University. N.E. was supported by NIH grant K08
747 MH123791, a Brain & Behavior Research Foundation Young Investigator Grant, a Burroughs
748 Wellcome Fund Career Award for Medical Scientists, a Stanford Society of Physician Scholars
749 Research Grant and the Simons Foundation Bridge to Independence Award. G.T. and A.R.W.
750 were supported by Stanford MedScholars grants. D.C.P. was supported by an NSF Graduate
751 Research Fellowship and an HHMI Gilliam Fellowship (with R.C.M.). R.C.M. was supported by a
752 Stanford University Wu Tsai Neurosciences Institute grant and NIH grant P50 DA042012.

753

754 **AUTHOR CONTRIBUTIONS**

755 N.E. and B.S.B. conceived the study with support from R.C.M. N.E. designed the experiments
756 with input from R.C.M. N.E. and R.C.M. interpreted the results and wrote the paper, which was
757 edited by all authors. A.R.W. designed and performed the sucrose photometry experiments.
758 G.C.T. designed and performed the inhibition and prefeeding experiments. G.C.T., A.K.O.,
759 A.N.S., A.M.G., and L.T. performed the optogenetics experiments. D.C.P. and J.T. contributed
760 to the design and analysis of the optogenetics experiments. D.C.P. performed the histological
761 verifications of fiber placements.

762

763 **DATA AVAILABILITY**

764 The datasets generated and analyzed during this study are included in this article and available
765 from the corresponding authors upon reasonable request.

766

767 **CODE AVAILABILITY**

768 Code used for data processing and analysis is available from the corresponding authors upon
769 reasonable request.

770

771 **COMPETING INTEREST DECLARATION**

772 All protocols used during this study are freely available for non-profit use from the corresponding
773 authors upon reasonable request. N.E. is a consultant for Boehringer Ingelheim. R.C.M. is on
774 the scientific advisory boards of MapLight Therapeutics, MindMed, Bright Minds Biosciences,
775 Cycleron and AZ Therapies.


776

777 **ADDITIONAL INFORMATION**

778 Correspondence and requests for materials should be addressed to Neir Eshel
779 (neshel@stanford.edu) and Robert C. Malenka (malenka@stanford.edu).

780

781




782

783 **Extended Data Fig. 1: Histological validation of fiber implant targeting.**

784 **a**, Bilateral fiber implants and GRAB-DA expression in a representative mouse used in the
 785 sucrose experiments. **b**, Fiber implants and GRAB-DA and ChRMINE expression in the NAc
 786 (left) and DLS (right) for representative mice in the optogenetic stimulation experiments. **c**, Fiber
 787 implants and GRAB-DA and NpHR expression in the NAc (left) and DLS (right) for
 788 representative mice in the optogenetic inhibition experiments. **d**, Fiber implant tip locations in

789 the NAc (top) and DLS (bottom) of mice used in the sucrose experiments. **e**, Fiber implant tip
790 locations in the NAc of mice expressing ChRMINE (top) or mScarlet (bottom) used in the
791 optogenetic stimulation experiments. **f**, Fiber implant tip locations in the DLS of mice expressing
792 ChRMINE (top) or mScarlet (bottom) used in the optogenetic stimulation experiments. **g**, Fiber
793 implant tip locations in the NAc (top) or DLS (bottom) of mice used in the anesthesia
794 experiments. **h**, Fiber implant tip locations in the NAc (top) or DLS (bottom) of mice used in the
795 prefeeding experiment. **i**, Fiber implant tip locations in the NAc (top) or DLS (bottom) of mice
796 used in the alternating FRs experiments. **j**, Fiber implant tip locations in the NAc (top) or DLS
797 (bottom) of mice used in the optogenetic inhibition experiments. Mice used in more than one
798 experiment have their fiber placement repeated in each experiment.




799

800 **Extended Data Fig. 2: The effect of FR on DA release does not depend on inter-reward**
801 **interval or the order of FRs.**

802 **a, b**, Left, Distribution of inter-reward intervals as a function of FR for mice with fibers in the NAc
803 (**a**) or DLS (**b**). Middle, Right, AUC of GRAB-DA photometry traces in response to reward cues
804 on trials with short (Middle, **a**: Kruskal-Wallis test, Kruskal-Wallis statistic=9.97, $P=0.04$; $n=12$; **b**:
805 Kruskal-Wallis test, Kruskal-Wallis statistic=10.99, $P=0.027$; $n=12$) or long (Right, **a**: Kruskal-
806 Wallis test, Kruskal-Wallis statistic=14.5, $P=0.006$; $n=12$; **b**: Kruskal-Wallis test, Kruskal-Wallis
807 statistic=15.9, $P=0.003$; $n=12$) inter-reward intervals. **c, d**, Left, Z-scored photometry traces of
808 GRAB-DA fluorescence in the NAc (**c**) or DLS (**d**) aligned to cue onset in sessions with a single
809 FR. Right, AUC of Z-scored photometry traces from 0 to 4s after cue onset as a function of FR
810 in the NAc (**c**: Mixed-effects model, $F_{4,20}=9.47$, $P=0.0002$; $n=12$) or DLS (**d**: Mixed-effects
811 model, $F_{4,20}=73.1$, $P<0.0001$; $n=12$). **e, g**, Left, Z-scored photometry traces of GRAB-DA
812 fluorescence in the NAc (**e**) or DLS (**g**) for mice performing a session with FRs presented in the
813 following order: 10, then 1, then 1, then 10. Right, Z-scored photometry traces for a separate
814 cohort of mice that performed a session with the following FR order: 1, then 10, then 10, then 1.
815 Top, fluorescence traces for the first two FRs presented in a session. Bottom, fluorescence
816 traces for the last two FRs presented in a session. **f, h**, Top, AUC of Z-scored photometry traces
817 in the NAc (**f**: Wilcoxon matched-pairs signed rank test, $W=36$, $P=0.0078$; $n=8$) or DLS (**h**:
818 Wilcoxon matched-pairs signed rank test, $W=28$, $P=0.016$; $n=7$) for consecutive blocks in which
819 FR1 is presented before FR10. Bottom, AUC of Z-scored photometry traces in the NAc (**f**:
820 Wilcoxon matched-pairs signed rank test, $W=28$, $P=0.016$; $n=7$) or DLS (**h**: Wilcoxon matched-
821 pairs signed rank test, $W=28$, $P=0.016$; $n=7$) for consecutive blocks in which FR10 is presented
822 before FR1. Regardless of FR order or timing within a session, FR10 trials always elicited
823 greater DA release than FR1 trials. * $P<0.05$, ** $P<0.01$, *** $P<0.001$.


824



825

826 **Extended Data Fig. 3: Representative examples of the inverse relationship between**
 827 **motivation and DA release for sucrose rewards.**

828 **a, c**, Free consumption parameter versus motivation parameter extracted from individual
 829 sessions in one representative mouse with recordings in the NAc (**a**) or DLS (**c**). **b, d**, Z-scored
 830 photometry traces of GRAB-DA fluorescence in the NAc (**b**) or DLS (**d**) for the sessions marked
 831 by colored circles in **a** and **c**, which differ primarily in motivation rather than free consumption. **e**,
 832 **f**, Demand curves for the sessions marked by colored circles in **a** and **c**. The demand curves
 833 have similar y-intercepts but differ in slope.



835 **Extended Data Fig. 4: The effect of FR on optogenetically-evoked DA release does not**
836 **depend on inter-stimulation interval or timing.**

837 **a, b**, Left, Distribution of inter-reward intervals as a function of FR for mice with fibers in the NAc
838 **(a)** or DLS **(b)**. Middle, Right, AUC of GRAB-DA photometry traces in response to optogenetic
839 stimulation on trials with short (Middle, **a**: Kruskal-Wallis test, Kruskal-Wallis statistic=74.5,
840 $P<0.0001$; $n=2946$ trials from 9 mice; **b**: Kruskal-Wallis test, Kruskal-Wallis statistic=10.8,
841 $P=0.029$; $n=1288$ trials from 14 mice) or long (Right, **a**: Kruskal-Wallis test, Kruskal-Wallis
842 statistic=10.1, $P=0.04$; $n=25$ trials from 9 mice; **b**: Kruskal-Wallis test, Kruskal-Wallis
843 statistic=9.45, $P=0.05$; $n=78$ trials from 14 mice) inter-reward intervals. **c, d**, Left, Z-scored
844 photometry traces of GRAB-DA fluorescence in the NAc **(c)** or DLS **(d)** in response to
845 optogenetic stimulation at different intervals for mice under anesthesia. Right, AUC of Z-scored
846 photometry traces in the NAc **(c**: Friedman test, Friedman statistic=3.28, $P=0.51$; $n=10$) or DLS
847 **(d**: Friedman test, Friedman statistic=0.98, $P=0.91$; $n=6$) as a function of inter-stimulation
848 interval. Intervals were chosen based on the average inter-reward intervals for each FR in the
849 demand task. **e, f**, Left, Z-scored photometry traces of GRAB-DA fluorescence in the NAc **(e)** or
850 DLS **(f)** during a session in which stimulation was given at random intervals without any
851 nose-poking requirement. Right, AUC of Z-scored photometry traces in the NAc **(e**: Wilcoxon
852 matched-pairs signed rank test, $W=-6$, $P=0.85$; $n=12$) or DLS **(f**: Wilcoxon matched-pairs signed
853 rank test, $W=-27$, $P=0.43$; $n=14$) in the first half or last half of each free-reward session. **g, h**,
854 Left, Z-scored photometry traces of GRAB-DA fluorescence in the NAc **(g)** or DLS **(h)** during a
855 session in which stimulation was always given at FR5. Right, AUC of Z-scored photometry
856 traces in the NAc **(g**: Wilcoxon matched-pairs signed rank test, $W=1$, $P>0.99$; $n=5$) or DLS **(h**:
857 Wilcoxon matched-pairs signed rank test, $W=61$, $P=0.058$; $n=14$) in the first half or last half of
858 each FR5 session. NS, not significant; * $P<0.05$, *** $P<0.001$. Error bars denote s.e.m.

